MSMaksim O. Shcheglov

Maksim O. Shcheglov

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Maksim O. Shcheglov has a total of 7 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Synthesis and Evaluation of Cytotoxic Activity of 2-Aryl-2-(3-Indolyl)Propionic Acid Derivatives

    by Alexander V. Aksenov, Nicolai A. Aksenov, Nikolai A. Arutiunov, Dmitrii A. Aksenov, Anna M. Zatsepilina, Daria I. Murashkina, Maksim O. Shcheglov, Sergei N. Ovcharov

    2-Aryl-2-(3-indolyl)acetohydroxamic acids have emerged as promising antitumor agents; however, their poor pharmacokinetic profile remains a significant drawback. To address this limitation, we have synthesized a homolog of such acids—specifically 2-aryl-2-(3-indolyl)propionic acid (IC50 > 100 mM (U87)), along with several other derivatives: ethyl ester (IC50 > 100 mM (U87)), hydroxamate (IC50 21.2 ± 1.0 mM (U87)) and hydrazide (IC50 > 100 mM (U87)). The cytotoxicity of these compounds against glioblastoma cell lines was evaluated and compared to that of the parent acetohydroxamic acid derivatives.

  • Open Access

    Synthesis and Evaluation of Cytotoxic Activity of 2-Aryl-2-(3-indolyl)propionic Acid Derivatives

    by Alexander V. Aksenov, Nicolai A. Aksenov, Nikolai A. Arutiunov, Dmitrii A. Aksenov, Anna M. Zatsepilina, Daria I. Murashkina, Maksim O. Shcheglov, Sergei N. Ovcharov

    2-Aryl-2-(3-indolyl)acetohydroxamic acids have emerged as promising antitumor agents; however, their poor pharmacokinetic profile remains a significant drawback. To address this limitation, we have synthesized homologs of such an acids—specifically 2-aryl-2-(3-indolyl)propionic acids—along with several other derivatives. The cytotoxicity of these compounds against glioblastoma cell lines was evaluated and compared to that of the parent acetohydroxamic acid derivatives.